



**COMPANY ANNOUNCEMENT
6 SEPTEMBER 2005**

NEUROSOLUTIONS AND GLAXOSMITHKLINE ENTER INTO REVENUE CONTRACT

NeuroDiscovery Ltd (**NeuroDiscovery**) (ASX Code:NDL), a neurology-focused biotechnology company, is pleased to announce its 100% subsidiary, NeuroSolutions Ltd (**NeuroSolutions** or **company**) and GlaxoSmithKline (**GSK**), a world leading pharmaceutical company, have entered into a significant revenue contract with GSK's UK Neurology & GastroIntestinal Centre of Excellence for Drug Discovery (N&GI CEDD) for the provision of electrophysiology services over the next six months.

GSK has been a major client of NeuroSolutions since the company commenced operations in 2001. NeuroSolutions has established a strong ongoing working relationship with GSK providing specialised electrophysiology services for a number of their pre-clinical drug discovery programmes.

NeuroSolution's Chief Executive Officer, Dr Alistair Dixon said, "We are extremely pleased to have yet again been chosen by GSK as a provider of choice in the field of electrophysiology services. GSK have been a tremendous partner and we look forward to continue to build and expand our relationship with the company over the coming years."

-ENDS-

For further information please contact:

*David McAuliffe
Executive Director
NeuroDiscovery Ltd
Mobile: 0408 994 313
macdavid@iinet.net.au*

Background Information

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd (ASX Code NDL).

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells, tissues or in vivo. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies. In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.